Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shanghai Yuesai Biotechnology

Request full access

Developing cell therapy drugs based on stem cell technology

ChinaFounded 2021Biotech & Life Sciences

About Shanghai Yuesai Biotechnology

Unixell is an innovative pharmaceutical company specializing in the development of next-generation cell therapy drugs. The company leverages a robust technology platform that includes unique reprogramming technology, stem cell separation, high-precision genetic editing, and autonomous research and development for tracking the SASCR spectrum. Unixell primarily focuses on treating neurodegenerative diseases, rare diseases, and tumors. The company collaborates with healthcare institutions like Reginald Hospital to advance treatments such as Parkinson's auto stem cell therapy. Unixell operates in the biopharmaceutical market, serving healthcare providers and patients who require advanced therapeutic solutions. The business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary cell therapy drugs. Revenue is generated through partnerships, licensing agreements, and the sale of its therapeutic products.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
22.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, Rare Diseases, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Feb 2026 $6.9M $69M Pan-Lin Asset Management ↗
SERIES A✓Equity / VC Apr 2024 $14M $55M Pudong Venture Capital ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Shanghai Yuesai Biotechnology website traffic

Latest recorded traffic for Shanghai Yuesai Biotechnology is 2K monthly website visits.

Latest monthly visits2K
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Addition TherapeuticsDeveloping of RNA-based genetic medicines using a non-viral insertion platform for chronic and rare diseases South San Francisco, United States Operational 67 $100M $400M
Harness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs Babraham, United Kingdom Operational
Trace NeuroscienceGenomic therapies for neurodegenerative diseases targeting UNC13A restoration South San Francisco, United States Operational
OlgramInnovations from the sea to tackle antibiotic resistance | Olgram Paris, France Operational
Asgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming Lund Municipality, Sweden Operational
Verve TherapeuticsFocused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary Cambridge, United States Acquired
Praxis Precision MedicinesDeveloping therapies for central nervous system disorders based on genetic insights into neuronal imbalance Cambridge, United States Operational
NapigenA biotech company that addresses novel genome engineering of various organisms such as plants, microbes and animals Wilmington, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Shanghai Yuesai Biotechnology in its local ecosystem

Live from Dealroom

The Shanghai Yuesai Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Pudong Venture Capital
  • Pan-Lin Asset Management

Other known investors1 additional known investor

  • Chinese Academy Of Sciences
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shanghai Yuesai Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shanghai Yuesai Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.